Small molecule · Inhibitor of polo-like kinase 1 (PLK1) · developed by Cardiff Oncology
Onvansertib is an orally bioavailable, ATP-competitive inhibitor of polo-like kinase 1 (PLK1), a serine/threonine kinase that regulates mitosis. By inhibiting PLK1 it disrupts mitosis, causing G2/M arrest and apoptosis in PLK1-overexpressing tumor cells. It is being studied in small-cell lung cancer and metastatic colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06106308 | Phase 2 | Metastatic Colorectal Cancer | Active not recruiting | PFE |
| NCT05450965 | Phase 2 | Small-cell Lung Cancer | Recruiting | CRDF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CRCKRAS/NRAS MutationMetastatic Colorectal CancerSmall Cell Lung CarcinomaSmall-cell Lung Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the CRDF page.
See CRDF's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRDF catalysts and pipeline →